Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: Comparison of clinical outcomes-Reference-Cited by-同舟云学术

Direct thrombin inhibitors for management of heparin-induced thrombocytopenia in patients receiving renal replacement therapy: Comparison of clinical outcomes

Published:2012-09-15 Issue:18 Volume:69 Page:1559-1567
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Abel Erik E.¹,Kane-Gill Sandra L.²,Seybert Amy L.³,Kellum John A.⁴

Affiliation:

1. The Ohio State University Medical Center, Columbus; at the time this study was conducted, he was Postgraduate Year 2 Resident in Cardiology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA.

2. Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, and Critical Care Medication Safety Officer, Department of Pharmacy, UPMC.

3. Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, and Cardiovascular Clinical Pharmacist, UPMC.

4. Department of Critical Care Medicine, University of Pittsburgh

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/69/18/1559/28361850/ajhp1559.pdf

Reference41 articles.

1. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient);Rice;Arch Intern Med.,2004

2. Heparin-induced thrombocytopenia: a ten-year retrospective;Warkentin;Annu Rev Med.,1999

3. A 14-year study of heparin-induced thrombocytopenia;Warkentin;Am J Med.,1996